Rich Pharmaceuticals Inc (RCHA) financial statements (2021 and earlier)

Company profile

Business Address 9595 WILSHIRE BLVD., SUITE 900
BEVERLY HILLS, CA 90212
State of Incorp. WY
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments641 16122
Cash and cash equivalents641 16122
Receivables1510    
Prepaid expense3    
Other undisclosed current assets  382 
Total current assets:2551323142
Noncurrent Assets
Property, plant and equipment12411 
Other undisclosed noncurrent assets12     
Total noncurrent assets:132411 
TOTAL ASSETS:3753724152
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,1711,2871,6701,1116327
Accounts payable3273501,139910181 
Accrued liabilities1,8449385302014517
Debt900920205402  
Derivative instruments and hedges, liabilities2,0992,608447140  
Due to related parties164977636 
Other undisclosed current liabilities1,209514  185 
Total current liabilities:6,3965,3792,3981,6598537
Noncurrent Liabilities
Long-term debt and lease obligation   6  
Long-term debt, excluding current maturities   6  
Liabilities, other than long-term debt   78  
Derivative instruments and hedges, liabilities   78  
Total noncurrent liabilities:   84  
Other undisclosed liabilities     24
Total liabilities:6,3965,3792,3981,74385331
Stockholders' equity
Stockholders' equity attributable to parent, including:(6,359)(5,326)(2,392)(1,719)(837)(29)
Preferred stock66666 
Common stock1,7091012161,5414143
Common stock, share subscribed but unissued, subscriptions receivable100   147 
Additional paid in capital5,9637,0126,5894,1692,04450
Accumulated deficit(14,137)(12,445)(9,203)(7,435)(3,301)(82)
Other undisclosed stockholders' equity attributable to parent    (147) 
Total stockholders' equity:(6,359)(5,326)(2,392)(1,719)(837)(29)
TOTAL LIABILITIES AND EQUITY:3753724152

Income statement (P&L) ($ in thousands)

3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
Revenues115     
Gain on disposition of assets for financial service operations52
Cost of revenue
(Cost of Goods and Services Sold)
 (46)(16)(201)(335) 
Gross profit:115(46)(16)(201)(335) 
Operating expenses(1,451)(952)(1,118)(3,606)(3,005)(31)
Other operating income (expense), net
(Other Expenses)
 2,290651(527)  
Other undisclosed operating income (loss) (2,244)(635)728335 
Operating loss:(1,336)(952)(1,118)(3,606)(3,005)(31)
Nonoperating expense(356)     
Interest and debt expense45029518563(0) 
Net loss:(1,242)(657)(932)(3,544)(3,005)(31)
Other undisclosed net loss attributable to parent(450)(2,585)(836)(590)  
Net loss available to common stockholders, diluted:(1,692)(3,241)(1,768)(4,134)(3,005)(31)

Comprehensive Income ($ in thousands)

3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
Net loss:(1,242)(657)(932)(3,544)(3,005)(31)
Comprehensive loss, net of tax, attributable to parent:(1,242)(657)(932)(3,544)(3,005)(31)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: